Midafotel

Drug Profile

Midafotel

Alternative Names: D-CPPene; SDZ EAA 494

Latest Information Update: 19 Jul 2010

Price : $50

At a glance

  • Originator Novartis
  • Developer BTG; Novartis
  • Class
  • Mechanism of Action Glutamate receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Brain injuries; Cognition disorders; Epilepsy

Most Recent Events

  • 19 Jul 2010 Discontinued - Phase-III for Brain injuries in Switzerland (unspecified route)
  • 19 Jul 2010 Discontinued - Phase-I for Cognition disorders in Switzerland (unspecified route)
  • 20 May 1999 D-CPPene is now called Midafotel
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top